Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.

A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine. He achieved a complete remission (CR) after two cycles of therapy, and he remained in remission during 1 year of treatment. He developed recurrent AML after discontinuation of decitabine. He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine.
AuthorsAmanda F Cashen, Hollie Devine, John DiPersio
JournalAmerican journal of hematology (Am J Hematol) Vol. 81 Issue 7 Pg. 543-5 (Jul 2006) ISSN: 0361-8609 [Print] United States
PMID16755561 (Publication Type: Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • decitabine
  • Azacitidine
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage)
  • Azacitidine (administration & dosage, analogs & derivatives)
  • Humans
  • Leukemia, Myeloid, Acute (prevention & control)
  • Male
  • Recurrence
  • Remission Induction
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: